Apotek Hjärtat is Sweden’s largest privately-owned pharmacy chain with around 390 pharmacies throughout the country. The company is owned by the grocery retailer Ica Gruppen. With this agreement, Efemia will now be available via the two largest pharmacy chains in Sweden.

“This is another important step forward in our efforts to increase Efemia’s visibility and availability on the Swedish market. With two nationwide pharmacy chains as resellers, we are now increasing our focus on reaching out to the product’s target group. This is done indirectly via educating relevant healthcare providers, and directly through digital campaigns and other marketing activities,” says Invent Medic’s CEO Karin Bryder.

Efemia will be included in Apotek Hjärtat’s assortment in the coming months.

For more information, please contact
Karin Bryder, CEO
Telephone: +46 (0) 723 811 710
Email: info@inventmedic.com

This information is information that Invent Medic Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 15, 2019.

About Apotek Hjärtat

Apotek Hjärtat is Sweden’s largest privately-owned pharmacy chain with around 390 pharmacies and over 3 000 employees. Together with customers and employees, the company is developing the pharmacy of tomorrow. Apotek Hjärtat has the ambition to improve the health and well-being of each customer with a more personal approach, a broader assortment and additional services. The pharmacies are located all over Sweden – in the city, in the countryside and on apotekhjartat.se.

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.